NCT02047149View on ClinicalTrials.gov

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

Zileuton (Zyflo®) Dasatinib (Sprycel®)

To determine the maximum dose of zileuton/dasatinib in subjects with CML

DRUG

Dosing with Zileuton/Dasatinib in CML

Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD

DRUG

Daily dosing of Zileuton/Dasatinib

Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD

DRUG

Daily dosing with Zileuton/Dasatinib for CML

Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD

Trial Locations (1)

01655

University of Massachusetts Medical School, Worcester

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Massachusetts, Worcester

OTHER